Stock PASG PASSAGE BIO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Passage Bio, Inc.

Equities

PASG

US7027121000

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-31 pm EDT 		5-day change 1st Jan Change
1.14 USD -0.87% Intraday chart for Passage Bio, Inc. +0.88% +12.87%
May. 15 Canaccord Genuity Trims Price Target on Passage Bio to $13 From $14, Maintains Buy Rating MT
May. 14 Passage Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Business Summary

Passage Bio, Inc. is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Its clinical product candidate, PBFT02, seeks to elevate progranulin levels to restore lysosomal function and slow disease progression across a variety of neurodegenerative diseases. PBFT02 utilizes an adeno-associated virus capsid to deliver a functional granulin gene, or GRN, encoding progranulin to the brain via intra cisterna magna administration. The lead indication for PBFT02 is frontotemporal dementia, or FTD, caused by progranulin deficiency, or FTD-GRN. Its development programs consist of PBFT02 for the treatment of FTD-GRN, PBFT02 for the treatment of FTD-C9orf72 and amyotrophic lateral sclerosis, and PBFT02 for the treatment of Alzheimer’s disease. Its clinical product candidates include PBGM01, PBKR03 and PBML04. It has one unnamed preclinical research program that explores multiple potential treatment targets for Huntington's disease.

Number of employees: 58

Managers

Managers TitleAgeSince
William Chou CEO
 Chief Executive Officer 51 22-10-09
James M. Wilson FOU
 Founder - 17-06-30
Kathleen Borthwick DFI
 Director of Finance/CFO 48 21-10-31
Mark Forman CTO
 Chief Tech/Sci/R&D Officer 60 21-07-29
Andrea Campanile CTO
 Chief Tech/Sci/R&D Officer - -
Alex Fotopoulos CTO
 Chief Tech/Sci/R&D Officer 55 19-06-30
Stuart M. Henderson IRC
 Investor Relations Contact - 21-01-31
Edgar Cale LAW
 General Counsel 60 19-08-31

Members of the board

Members of the board TitleAgeSince
Maxine Gowen CHM
 Chairman 66 21-02-17
Saqib Islam BRD
 Director/Board Member 54 19-03-28
Athena Countouriotis BRD
 Director/Board Member 52 20-01-31
Sandipkumar S. Kapadia BRD
 Director/Board Member 54 19-11-30
Derrell Porter BRD
 Director/Board Member 53 21-05-26
William Chou CEO
 Chief Executive Officer 51 22-10-09
Dolan Sondhi BRD
 Director/Board Member 53 23-07-26

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 61,640,596 61,339,949 ( 99.51 %) 0 99.51 %

Shareholders

NameEquities%Valuation
OrbiMed Advisors Private Equity
16.43 %
10,124,576 16.43 % 12 M $
Lynx1 Capital Management LP
7.865 %
4,845,871 7.865 % 6 M $
Vestal Point Capital LP
7.304 %
4,500,000 7.304 % 5 M $
Versant Venture Management LLC
6.535 %
4,026,417 6.535 % 5 M $
New Leaf Venture Partners LLC
4.054 %
2,497,922 4.054 % 3 M $
Vanguard Global Advisers LLC
3.362 %
2,071,538 3.362 % 3 M $
Tang Capital Management LLC
2.435 %
1,500,000 2.435 % 2 M $
Renaissance Technologies LLC
1.957 %
1,205,524 1.957 % 1 M $
Acadian Asset Management LLC
1.560 %
961,271 1.560 % 1 M $
BlackRock Advisors LLC
1.460 %
899,282 1.460 % 1 M $

Company contact information

Passage Bio, Inc.

One Commerce Square 2005 Market Street

19103, Philadelphia

+

http://www.passagebio.com
address Passage Bio, Inc.(PASG)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.14 USD
Average target price
6.75 USD
Spread / Average Target
+492.11%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
PASSAGE BIO, INC. Stock Passage Bio, Inc.
+12.87% 70.27M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+11.91% 118B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+11.60% 106B
BIONTECH SE Stock BioNTech SE
-4.68% 24.28B
ARGENX SE Stock argenx SE
-0.82% 21.96B
GENMAB A/S Stock Genmab A/S
-10.12% 18.16B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-42.12% 16.37B
BEIGENE, LTD. Stock BeiGene, Ltd.
-17.47% 15.56B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+2.77% 13.63B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+34.58% 12.27B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. PASG Stock
  4. Company Passage Bio, Inc.